REVIEW ARTICLE
Off label uses of hyaluronic acid fillers: A review
Poonam Tapsale,
Belma Türsen,
Ümit Türsen,
Poonam Tapsale
Deccan Multispeciality Hardikar Hospital, Pune, Maharashtra, India
Search for more papers by this authorBelma Türsen
School of Health Sciences, Toros University, Mersin, Turkey
Search for more papers by this authorCorresponding Author
Ümit Türsen
Department in Dermatology, School of Medicine, Mersin University, Mersin, Turkey
Correspondence
Ümit Türsen, Department in Dermatology, School of Medicine, Mersin University, Mersin, Turkey.
Email: [email protected]
Search for more papers by this authorPoonam Tapsale,
Belma Türsen,
Ümit Türsen,
Poonam Tapsale
Deccan Multispeciality Hardikar Hospital, Pune, Maharashtra, India
Search for more papers by this authorBelma Türsen
School of Health Sciences, Toros University, Mersin, Turkey
Search for more papers by this authorCorresponding Author
Ümit Türsen
Department in Dermatology, School of Medicine, Mersin University, Mersin, Turkey
Correspondence
Ümit Türsen, Department in Dermatology, School of Medicine, Mersin University, Mersin, Turkey.
Email: [email protected]
Search for more papers by this authorAbstract
Food and Drug Administration approved indications of hyaluronic acid fillers include some facial wrinkles or skin folds like naso-labial folds, perioral wrinkles, volumization of lip, cheek, chin, and dorsal region of the hands, also acne scars and lipoatrophy of human immunodeficiency virus positive patients. This article reviews the off-label indications of hyaluronic acid fillers such as connective tissue disorders (lupus erythematosus, scleroderma, and dermatomyositis), lipoatrophy associated with other diseases, breast volumization, giving volume to buttocks and the feet, implant into bone, tendon, ligament or muscle, injection to glabella, nose, periorbital region, forehead, or neck.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
Research data are not shared.
REFERENCES
- 1https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/fda-approved-dermal-fillers. Accessed December 26, 2020.
- 2Robitschek J, Wang D, Hall D. Treatment of linear scleroderma en coup de sabre with AlloDerm tissue matrix. Otolaryngol Head Neck Surg. 2008; 138: 540-541.
- 3Oh CK, Lee J, Jang BS, et al. Treatment of atrophies secondary to trilinear scleroderma en coup de sabre by autologous tissue cocktail injection. Dermatol Surg. 2003; 29: 1073-1075.
- 4Lapiere JC, Aasi S, Cook B, Montalvo A. Successful correction of depressed scars of the forehead secondary to trauma and morphea en coup de sabre by en bloc autologous dermal fat graft. Dermatol Surg. 2000; 26: 793-797.
- 5Karaaltin MV, Akpinar AC, Baghaki S, Akpinar F. Treatment of en coup de sabre deformity with adipose-derived regenerative cell-enriched fat graft. J Craniofac Surg. 2012; 23: e103-e105.
- 6Bader RS, Johnson DL. Dermal Fillers. http://emedicine.medscape.com/article/5066-overview. 2008.
- 7De Maio M, Rzany B. Injectable Fillers in Aesthetic Medicine. Springer; 2006.
- 8Hirsch RJ, Brody HJ, Carruthers JDA. Hyaluronidase in the office: a necessity for every dermasurgeon that injects HA. J Cosmet Laser Ther. 2007; 9: 182-185.
- 9Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol. 2011; 64: 1-34.
- 10Kavasi RM, Berdiaki A, Spyridaki I, et al. HA metabolism in skin homeostasis and inflammatory disease. Food Chem Toxicol. 2017; 101: 128-138.
- 11Neuman MG, Nanau RM, Oruña-Sanchez L, Coto GJ. Hyaluronic acid and wound healing. J Pharm Pharm Sci. 2015; 18: 53-60.
- 12Keen MA. Hyaluronic acid in dermatology. Skinmed. 2017; 1: 441-448.
- 13Koger C, Cohen J. The lasting effects of fillers through neocollagenesis. Dermatologist. 2014; 22:40-50.
- 14Wang F, Garza LA, Kang S, et al. In vivo stimulation of de novo collagen productioncaused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol. 2007; 143: 155-163.
- 15Goa KL, Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs. 1994; 47: 536-566.
- 16Cox SE, Soderberg JM. Idiopathic hemifacial atrophy treated with serial injections of calcium hydroxylapatite. Dermatol Surg. 2010; 34: 542-545.
- 17Lane TK, Cheung J, Schaffer JV. Parry–Romberg syndrome with coexistent morphea. Dermatol Online J. 2008; 14: 21.
- 18Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011; 65: 925-941.
- 19BielsaMarsol I. Update on the classification and treatment of localized scleroderma. Actas Dermosifiliogr. 2013; 104: 654-666.
- 20Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006; 18(6): 606-613.
- 21Sharquie KE, Noaimi AA, Abdulqader ET. Clinical and histopathological evaluation of pigmented morphea with new insight in relation to etiopathogenesis of the disease. A thesis presented to the Arabic Board for Medical Specialization, 2018.
- 22Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003; 48: 2246-2255.
- 23Bolognia J, Schaffer JV, Duncan KO, Ko CJ. Dermatology Essentials. Saunders/Elsevier; 2014.
- 24Firestein GS, Gabriel SE, McInnes IB, O'Dell JR. Kelley and Firestein's Textbook of Rheumatology. 10th ed. Elsevier; 2017.
10.1016/B978-0-323-31696-5.00069-3 Google Scholar
- 25Fett N, Werth VP. Update on morphea: Part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011; 64: 217-228.
- 26Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabriel SE. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997; 24: 73-80.
- 27Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015; 23(1):15002.
- 28Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev. 2011; 10(10): 590-594.
- 29Giacomelli R, Afeltra A, Alunno A, et al. International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017; 16(9): 911-924.
- 30Brown M, O'Reilly S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin Exp Immunol. 2018; 195(3): 310-321.
- 31Albilia JB, Lam DK, Blanas N, Clokie CML, Sándor GKB. Small mouths… big problems? A review of scleroderma and its oral health implications. J Calif Dent Assoc. 2007; 73(9): 831-836.
- 32Fakhari A, Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler, and in osteoarthritis treatment. Acta Biomater. 2013; 9(7): 7081-7092.
- 33Laurent TC, Fraser JR. Hyaluronan. Federation Am Soc Exper Biol J. 1992; 6(7): 2397-2404.
- 34Thareja SK, Sadhwani D, Fenske NA. En coupe de sabre morphea treated with hyaluronic acid filler. Report of a case and review of the literature. Int J Dermatol. 2015; 54: 823-826.
- 35Choksi AN, Orringer JS. Linear morphea-induced atrophy treated with hyaluronic acid filler injections. Dermatol Surg. 2011; 37: 880-883.
- 36Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injection in photodamaged human skin. Arch Dermatol. 2007; 143(2): 155-163.
- 37Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000; 356: 1423-1430.
- 38Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000; 1 0(9): 546-550.
- 39James J, Carruthers A, Carruthers J. HIV-associated facial lipoatrophy. Dermatol Surg. 2002; 28: 979-986.
- 40Fallacara A, Manfredini S, Durini E, Vertuani S. Hyaluronic acid fillers in soft tissue regeneration. Facial Plast Surg. 2017; 33(1): 87-96.
- 41Gooderham M, Solish N. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg. 2005; 31: 104-108.
- 42Jones D. HIV facial lipoatrophy: causes and treatment options. Dermatol Surg. 2005; 31: 1519-1529.
- 43Hausauer AK, Jones DH. Long-term correction of iatrogenic lipoatrophy with volumizing hyaluronic acid filler. Dermatol Surg. 2018; 44(Suppl 1): S60-S62.
- 44Afra TP, Vinay K, Razmi TM, Narang T, Dogra S. Hyaluronic acid fillers for correcting midface volume deficit in Barraquer-Simons syndrome. J Cosmet Dermatol. 2019; 18: 1264-1266. doi:10.1111/jocd.12847
- 45Kopera D, Ivezic-Schoenfeld Z, Federspiel IG, Grablowitz D, Gehl B, Prinz M. Treatment of facial lipoatrophy, morphological asymmetry, or debilitating scars with the hyaluronic acid dermal FILLER princess® FILLER. Clin Cosmet Investig Dermatol. 2018; 11: 621-628.
- 46Koh PW, Shafi H. Non-responsive breast cellulitis after hyaluronic acid filler injection. Int J Infect Dis. 2018; 70: 57-58.
- 47Goldberg DJ. Legal ramifications of off-label filler use. Dermatol Ther. 2006; 19(3): 189-193.
